Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

IKCS 2019: Comparing Patient- and Clinician-Reported Performance Status

By: Joseph Fanelli
Posted: Tuesday, December 10, 2019

When it comes to rating the performance status of patients undergoing treatment for advanced renal cell carcinoma, clinicians may tend to overestimate Eastern Cooperative Oncology Group (ECOG) performance status scores, compared with patients self-reported assessments, according to findings presented at the 2019 International Kidney Cancer Symposium (IKCS) in Miami. According to Christane Bergerot, PhD, of the City of Hope National Medical Center, Duarte, California, and colleagues, “These findings underscore the potential role of self-reported ECOG [performance status], especially given its association with both [quality of life] and emotional well-being.”

In this study, 85 patients with advanced renal cell carcinoma who were receiving treatment at a single institution were enrolled. Nearly three-quarters of these patients were men, and the median age of patients was 63. The patients were assessed for performance status, quality of life, and emotional well-being. Of the group, 47% were receiving first-line therapy, and 21% were receiving second-line therapy.

The investigators found that clinicians were more likely to classify patients with an ECOG performance status of 0 than were patients themselves (94% vs. 68%, respectively). Worse ECOG performance status scores were associated with poorer quality of life among both clinician-reported and patient-reported assessments. According to the authors, poorer emotional well-being seemed to be associated with self-reported ECOG performance status scores, but not with clinician performance status ratings.

Disclosure: For full disclosures of the study authors, visit www.kidneycancer.org/.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.